All stock lists
Corteva, Inc. (New York Stock Exchange:CTVA)
US · Delayed Price · Currency is USD
Also listed: 2X0.DEBasic Materials · Agricultural Inputs
12.32-0.13 (-1.00%)
Insider Score
––Not scored
CTVA Insider Score
Insiders here have filed 8 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
CTVA analyst forecast
CTVA analyst consensus
Moderate Buy7 ratings
Buy 5 Hold 2 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
CTVA 12-month price target
$61.90+403.5% upsideaverage of 10 firms
$101.00High
$17.00Low
Best analysts covering CTVA
- Oppenheimer100%success rate · 8 calls
- B of A Securities100%success rate · 3 calls
- UBS89%success rate · 9 calls
- Argus Research80%success rate · 5 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
CTVA analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | UBS | Neutral | — | — | Reiterated | 2026-10-12 |
| Goldman Sachs | — | $20.00 | +38.4% | — | 2026-10-08 | |
| — | Keybanc | Overweight | — | — | Upgraded | 2026-10-07 |
| RBC Capital | — | $17.00 | +22.2% | — | 2026-10-07 | |
| KeyBanc | — | $17.00 | +22.2% | — | 2026-10-07 | |
| — | JP Morgan | Overweight | — | — | Upgraded | 2026-10-06 |
| Oppenheimer | — | $17.00 | +42.6% | — | 2026-10-05 | |
| Oppenheimer | — | $95.00 | +18.1% | — | 2026-09-24 | |
| — | Argus Research | Buy | — | — | Reiterated | 2026-09-18 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-09-17 |
| BMO Capital | Outperform | $95.00 | +14.3% | Reiterated | 2026-09-16 | |
| — | UBS | Neutral | — | — | Reiterated | 2026-09-16 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-09-16 |
| — | UBS | Neutral | — | — | Reiterated | 2026-08-18 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-08-03 |
| — | UBS | Neutral | — | — | Reiterated | 2026-08-03 |
| BMO Capital | Outperform | $100.00 | +27.0% | Reiterated | 2026-08-03 | |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-08-03 |
| Deutsche Bank | — | $101.00 | +29.9% | — | 2026-08-03 | |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-07-23 |
| RBC Capital | Outperform | $103.00 | +18.7% | Reiterated | 2026-07-21 | |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-07-20 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-14 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-02 |
| Barclays | Overweight | $91.00 | +22.2% | Reiterated | 2026-06-11 | |
| UBS | Neutral | $86.00 | +13.4% | Reiterated | 2026-06-09 | |
| Morgan Stanley | Overweight | $95.00 | +18.9% | Reiterated | 2026-05-28 | |
| — | UBS | Neutral | — | — | Reiterated | 2026-05-07 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-05-07 |
| RBC Capital | Outperform | $95.00 | +20.8% | Reiterated | 2026-04-24 | |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-04-22 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-04-21 |
| — | UBS | Neutral | — | — | Reiterated | 2026-04-09 |
| — | Argus Research | Buy | — | — | Reiterated | 2026-03-31 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-02-17 |
| UBS | — | $80.00 | +10.2% | — | 2026-02-09 | |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-02-05 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-02-05 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-02-05 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2026-02-05 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-01-27 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-01-21 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-01-21 |
| Mizuho | Outperform | $80.00 | +13.5% | Reiterated | 2026-01-16 | |
| — | Citigroup | Neutral | — | — | Reiterated | 2025-12-18 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-11 |
| — | UBS | Buy | — | — | Reiterated | 2025-10-30 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-10-16 |
| — | Argus Research | Buy | — | — | Reiterated | 2025-10-13 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-10-08 |
| — | UBS | Buy | — | — | Reiterated | 2025-10-06 |
| — | Keybanc | Sector Weight | — | — | Downgraded | 2025-10-03 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2025-10-02 |
| — | Citigroup | Neutral | — | — | Downgraded | 2025-10-02 |
| — | Barclays | Overweight | — | — | Upgraded | 2025-08-13 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-08-08 |
| — | Keybanc | Overweight | — | — | Reiterated | 2025-08-08 |
| — | UBS | Buy | — | — | Reiterated | 2025-08-07 |
CTVA earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-04 | 0.03 | 0.03 | $4.24B | $3.91B |
| 2026-05-06 | 0.18 | 0.23 | $4.64B | $4.91B |
| 2026-07-30 | 0.34 | 0.35 | $6.60B | $6.38B |
| 2026-11-11 | 0.02 | 0.00 | $1.77B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.